Skip to content

US · BMRA

Biomerica, Inc.

Programmatic access: InvestorsCraft Valuation API · catalog

Sector
Healthcare · Medical - Devices
Headquarters
Irvine, CA 92614

Price at previous close

$2.31

Market cap 5.01M

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for Biomerica, Inc. (BMRA) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biomerica, Inc.

        Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

        CEO
        Zackary S. Irani
        Employees
        54
        Beta
        0.33

        Peer comparison

        Same-industry comparables, ranked by market cap.

        The peer comparison table is shown only to users with a Pro subscription.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.